CUE
Bearish signalScored 2026-10-18 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Cue Biopharma, Inc.
- Nom
- Cue Biopharma, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $135.6M
- Employés
- 29
- PDG
- Shao-Lee Lin
- Site web
- https://www.cuebiopharma.com
- Marché
- BRNSCOEPEQIOBTIPSCMDCX
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11 087 titres (~304 892,50 $ US)
- Insiders
- Lin Shao-Lee
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$583,139
Avg sell (VWAP, 90d window) $28.70 vs last close $16.08 (-44.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-12
- Liquidity
- Thin $4,692,274/day · 20d vol
- Last synced
-
2026-10-19 21:10:19
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | Lin Shao-Lee | Sell · S | 1,087 | $28.05 | $30,490 | Form 4 |
| 2026-10-12 | Meluzio Michael Vincent | Sell · S | 1,144 | $28.05 | $32,089 | Form 4 |
| 2026-10-12 | Ray Sumita | Sell · S | 1,844 | $28.05 | $51,724 | Form 4 |
| 2026-08-13 | Meluzio Michael Vincent | Sell · S | 3 | $31.13 | $93 | Form 4 |
| 2026-08-13 | Ray Sumita | Sell · S | 4 | $31.13 | $125 | Form 4 |
| 2026-08-13 | Lin Shao-Lee | Sell · S | 10,460 | $29.48 | $308,361 | Form 4 |
| 2026-08-12 | Lin Shao-Lee | Sell · S | 5,775 | $27.75 | $160,256 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-18 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CUE combines severe financial distress (liquidity score 45, fundamentals trend score 25) with a weak catalyst signal (score 25, confidence 0.55), as positive Phase II CUE-221 results are materially offset by significant…
The first sentence of the analysis written for CUE on 2026-10-18 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.74 · operating margin -97% — readings disagree
Suggested stop 9.38, nearest stored support minus 0.5 ATR(41.7% under the last close). Reward/risk to the next stored resistance is 1.67. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-09-28 Cue Biopharma''s CUE-221 Hits Phase II Goals, Shows Durable CSU Response Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
- 2026-09-28 Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response Cue Biopharma (NASDAQ: CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluated subcutaneous CUE-221 at doses of 1 mg/kg, 2 mg/kg and 4 mg/kg, administered every four weeks. The trial
- 2026-09-21 Cue Biopharma: Initiating ''Buy'' Based On CUE-221 Trial Win CSU With Novel Dual MOA I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221''s novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food allergy, targeting large market opportunities.
- 2026-09-21 Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
- 2026-09-21 What''s Going on With Cue Biopharma Stock on Monday? Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
- 2026-09-20 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study
- 2026-09-18 This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 2026-08-24 SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company''s shareholders. The investigation seeks to determine whether Cue Biopharma''s directors breached their fiduciary duties in connection with recent corporate actions.
- 2026-08-14 Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.
- 2026-08-03 Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | -593.9% | 100.0% | 111.9% | |
| Ebit Margin | -93.7% | -429.4% | -901.4% | -4200.6% | -292.3% | |
| Ebitda Margin | -90.2% | -404.1% | -838.8% | -4055.5% | -304.1% | |
| Operating Profit Margin | -96.6% | -446.9% | -949.9% | -4275.1% | -292.6% | |
| Pretax Profit Margin | -95.0% | -438.0% | -924.1% | -4257.8% | -292.3% | |
| Continuous Operations Profit Margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | |
| Net Profit Margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | |
| Bottom Line Profit Margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | |
| Current Ratio | 2.741 | 1.836 | 3.012 | 6.684 | 5.354 | |
| Quick Ratio | 2.741 | 1.836 | 3.012 | 6.684 | 5.354 | |
| Solvency Ratio | -1.625 | -2.608 | -1.935 | -2.000 | -2.565 | |
| Cash Ratio | 2.011 | 1.641 | 2.840 | 4.470 | 5.034 | |
| Price To Earnings Ratio | -1.090 | -1.514 | -2.378 | -1.913 | -8.021 | |
| Price To Earnings Growth Ratio | 0.018 | 0.043 | 0.093 | -0.337 | 0.834 | |
| Forward Price To Earnings Growth Ratio | 0.018 | 0.043 | 0.093 | -0.337 | 0.834 | |
| Price To Earnings Diluted Ratio | -1.090 | -1.514 | -2.378 | -1.913 | -8.021 | |
| Price To Earnings Diluted Growth Ratio | 0.018 | 0.043 | 0.093 | -0.337 | 0.834 | |
| Price To Book Ratio | 1.094 | 3.509 | 3.257 | 1.547 | 5.403 | |
| Price To Sales Ratio | 1.053 | 6.611 | 22.002 | 81.606 | 23.682 | |
| Price To Free Cash Flow Ratio | -1.323 | -1.687 | -3.023 | -2.420 | -8.902 | |
| Price To Operating Cash Flow Ratio | -1.334 | -1.690 | -3.023 | -2.430 | -9.111 | |
| Debt To Assets Ratio | 0.099 | 0.276 | 0.239 | 0.212 | 0.144 | |
| Debt To Equity Ratio | 0.159 | 0.507 | 0.396 | 0.294 | 0.184 | |
| Debt To Capital Ratio | 0.137 | 0.337 | 0.284 | 0.227 | 0.155 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.102 | 0.109 | 0.000 | |
| Financial Leverage Ratio | 1.597 | 1.840 | 1.659 | 1.390 | 1.273 | |
| Working Capital Turnover Ratio | 1.572 | 0.405 | 0.110 | 0.021 | 0.235 | |
| Operating Cash Flow Ratio | -1.607 | -2.654 | -2.340 | -3.620 | -3.037 | |
| Operating Cash Flow Sales Ratio | -0.790 | -3.912 | -7.279 | -33.579 | -2.599 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | 1.002 | 1.000 | 1.004 | 1.024 | |
| Debt Service Coverage Ratio | -70.832 | -7.317 | -8.843 | -18.862 | -23.341 | |
| Interest Coverage Ratio | -74.289 | -52.136 | -41.887 | -74.564 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -8.384 | -10.084 | -21.297 | -19.733 | |
| Operating Cash Flow Coverage Ratio | -5.167 | -4.093 | -2.719 | -2.164 | -3.231 | |
| Capital Expenditure Coverage Ratio | -122.525 | -550.439 | 0.000 | -244.480 | -42.536 | |
| Dividend Paid And Capex Coverage Ratio | -122.525 | -550.439 | 0.000 | -244.480 | -42.536 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.241 | -1.274 | -1.889 | -1.373 | -6.634 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | ▲136.4% |
| Ebit Margin | -93.7% | ▲335.7% | ▲1089.7% |
| Ebitda Margin | -90.2% | ▲313.9% | ▲1048.3% |
| Operating Profit Margin | -96.6% | ▲350.3% | ▲1115.6% |
| Pretax Profit Margin | -95.0% | ▲342.9% | ▲1106.4% |
| Continuous Operations Profit Margin | -96.9% | ▲341.1% | ▲1105.6% |
| Net Profit Margin | -96.9% | ▲341.1% | ▲1105.6% |
| Bottom Line Profit Margin | -96.9% | ▲341.1% | ▲1105.6% |
| Current Ratio | 2.741 | ▲0.904 | ▼-1.185 |
| Quick Ratio | 2.741 | ▲0.904 | ▼-1.185 |
| Solvency Ratio | -1.625 | ▲0.983 | ▲0.522 |
| Cash Ratio | 2.011 | ▲0.370 | ▼-1.188 |
| Price To Earnings Ratio | -1.091 | ▲0.423 | ▲1.893 |
| Price To Earnings Growth Ratio | 0.018 | ▼-0.025 | ▼-0.112 |
| Forward Price To Earnings Growth Ratio | 0.018 | ▼-0.025 | ▼-0.112 |
| Price To Earnings Diluted Ratio | -1.091 | ▲0.423 | ▲1.893 |
| Price To Earnings Diluted Growth Ratio | 0.018 | ▼-0.025 | ▼-0.112 |
| Price To Book Ratio | 1.094 | ▼-2.414 | ▼-1.868 |
| Price To Sales Ratio | 1.053 | ▼-5.558 | ▼-25.938 |
| Price To Free Cash Flow Ratio | -1.323 | ▲0.364 | ▲2.148 |
| Price To Operating Cash Flow Ratio | -1.334 | ▲0.356 | ▲2.184 |
| Debt To Assets Ratio | 0.099 | ▼-0.176 | ▼-0.095 |
| Debt To Equity Ratio | 0.159 | ▼-0.348 | ▼-0.149 |
| Debt To Capital Ratio | 0.137 | ▼-0.200 | ▼-0.091 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.042 |
| Financial Leverage Ratio | 1.597 | ▼-0.243 | ▲0.045 |
| Working Capital Turnover Ratio | 1.572 | ▲1.167 | ▲1.104 |
| Operating Cash Flow Ratio | -1.607 | ▲1.047 | ▲1.044 |
| Operating Cash Flow Sales Ratio | -0.790 | ▲3.122 | ▲8.842 |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | ▲0.006 | ▲0.001 |
| Debt Service Coverage Ratio | -70.832 | ▼-63.515 | ▼-44.993 |
| Interest Coverage Ratio | -74.288 | ▼-22.153 | ▼-25.713 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲8.384 | ▲11.899 |
| Operating Cash Flow Coverage Ratio | -5.167 | ▼-1.074 | ▼-1.692 |
| Capital Expenditure Coverage Ratio | -122.525 | ▲427.914 | ▲69.471 |
| Dividend Paid And Capex Coverage Ratio | -122.525 | ▲427.914 | ▲69.471 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.241 | ▲1.033 | ▲2.041 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $28.9M | $61.4M | $120.8M | $101.6M | $353.8M | |
| Enterprise value | $6.0M | $47.8M | $87.0M | $69.3M | $301.5M | |
| EV / Sales | 0.22x | 5.15x | 15.84x | 55.66x | 20.18x | |
| EV / Op. cash flow | -0.28x | -1.32x | -2.18x | -1.66x | -7.76x | |
| EV / Free cash flow | -0.27x | -1.31x | -2.18x | -1.65x | -7.58x | |
| EV / EBITDA | -0.24x | -1.27x | -1.89x | -1.37x | -6.63x | |
| Net debt / EBITDA | 0.93x | 0.36x | 0.73x | 0.64x | 1.15x | |
| Current ratio | 2.74x | 1.84x | 3.01x | 6.68x | 5.35x | |
| Income quality | 0.81x | 0.89x | 0.79x | 0.79x | 0.88x | |
| Graham net-net | $5 | $5 | $17 | $43 | $47 | |
| Tax burden | 101.9% | 100.0% | 100.0% | 100.0% | 101.1% | |
| Interest burden | 101.4% | 102.0% | 102.5% | 101.4% | 100.0% | |
| Working capital | $23.5M | $11.4M | $34.4M | $65.6M | $55.7M | |
| Invested capital | $27.8M | $16.3M | $41.5M | $76.3M | $67.6M | |
| Return on assets | -63.0% | -126.4% | -82.5% | -58.1% | -53.0% | |
| Operating ROA | -71.3% | -88.6% | -68.3% | -60.9% | -47.8% | |
| Return on tangible assets | -63.0% | -126.4% | -82.5% | -58.1% | -53.0% | |
| Return on equity | -100.6% | -232.4% | -136.8% | -80.7% | -67.4% | |
| Return on invested capital | -86.6% | -157.3% | -100.7% | -62.6% | -56.4% | |
| Return on capital employed | -92.3% | -224.3% | -117.3% | -66.8% | -61.9% | |
| Earnings yield | -92.0% | -66.2% | -42.0% | -52.2% | -12.5% | |
| Free cash flow yield | -75.6% | -59.3% | -33.1% | -41.3% | -11.2% | |
| Capex / Op. cash flow | -0.8% | -0.2% | 0.0% | -0.4% | -2.4% | |
| Capex / Depreciation | 18.5% | 2.8% | 0.0% | 9.5% | -51.4% | |
| Capex / Sales | 0.6% | 0.7% | 0.0% | 13.7% | 6.1% | |
| SG&A / Sales | 59.1% | 157.0% | 303.8% | 1298.7% | 115.8% | |
| R&D / Sales | 137.4% | 390.8% | 743.2% | 3098.6% | 276.7% | |
| Stock comp / Sales | 17.3% | 73.7% | 149.0% | 762.7% | 77.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 99d | 37d | 113d | 17d | 77d | |
| Days payables outstanding | 0d | 0d | 34d | 0d | -532d | |
| Operating cycle | 99d | 37d | 113d | 17d | 77d | |
| Cash conversion cycle | 99d | 37d | 79d | 17d | 609d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years